Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea

← catalyst calendar

NCT07621653 · readout in 461 d

Sponsored by Sanofi (industry) · SNY — their whole pipeline →.

Phase

—

Status

Recruiting

Study type

Observational

Enrollment

706estimated

Sites

Country

South Korea

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-07-01

actual

When the study began enrolling

Primary completion

2027-11-23

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-11-23

estimated

The whole study's end, after follow-up

First posted

2026-06-02

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Meningococcal Immunization
Healthy Volunteers

Intervention

Biological: Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine — also filed as MenQuadfi®

Primary outcomes

what the primary-completion date above is the date OF

Number of participants with solicited injection site and systemic reactions

measured Up to 7 days after vaccination

Number of participants with unsolicited non-serious Adverse Events (AEs) and Adverse Drug Reactions (ADRs), including unexpected AEs and ADRs

measured Up to 30 days after vaccination

Number of participants with Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI), and Serious Adverse Drug Reactions (SADRs)

measured From Day 01 up to the end of the study (approximately 44 days after inclusion in individuals aged 2-55 years; approximately 4 months in infants aged 6 months to <24 months; approximately 13 months in infants aged 6 weeks to <6 months)

Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed